2026-01-15 - Analysis Report
**Abbott Laboratories (ABT) Financial Report**
=====================================================

### Quick Facts

* **Ticker:** ABT
* **Company Name:** Abbott Laboratories
* **Analysis Period:** Recent stock price fluctuations, financial data, and analyst opinions from 2024 to 2025

### Return Rate Comparison
---------------------------------

* **ABT Return Rate (rate):** 36.06%
* **S&P 500 (VOO) Return Rate (rate_vs):** 92.89%
* **Degree of Divergence:** -55.83% (-58.60 - 92.89)

### Alpha, Beta Analysis
-------------------------

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 32.0% | 14.5% | 29.0% | 1.1  | 125.9  |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0  | 151.2  |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9  | 190.6  |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8  | 244.9  |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8  | 191.1  |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7  | 191.6  |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7  | 196.9  |
| 2023-2025  | 10.0% | 16.0% | -52.0% | 0.3  | 218.1  |

### Recent Stock Price Fluctuations
-----------------------------------

* **Close:** $125.00
* **Last-Market:** $125.00 (change: 0.56)
* **5-day SMA:** $125.21
* **20-day SMA:** $125.53
* **60-day SMA:** $126.11

### RSI, PPO Analysis
-----------------------

* **MRI (Market Risk Indicator):** 0.70
* **RSI (Relative Strength Index):** 52.06
* **PPO (Price Percent):** -0.02
* **Buy Signal:** True
* **Risk Level:** Medium
* **Expected Return:** -1586.60%

### Recent News & Events
-------------------------

* **[2026-01-14] Abbott Laboratories $ABT Stock Holdings Cut by Exencial Wealth Advisors LLC - MarketBeat (news.google.com)**
* **[2026-01-12] Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance (news.google.com)**
* **[2026-01-14] The Bull Case For Abbott Laboratories (ABT) Could Change Following Libre Assist AI Launch In Diabetes Care - simplywall.st (news.google.com)**
* **[2025-12-12] Investors - Abbott (news.google.com)**
* **[2025-12-18] 2 Dividend Stocks to Buy for 2026 and Beyond - The Motley Fool (news.google.com)**
* **[2025-12-24] Abbott Laboratories Shrugs Off Tariffs & China Headwinds With 7% Dividend Raise (NYSE:ABT) - Seeking Alpha (news.google.com)**

### Analyst Opinions
---------------------

**Analyst Consensus:**
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.71 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): $144.75 / $169.00 / $122.00

### Recent Earnings Analysis
-----------------------------

| Date | EPS | Revenue |
| 2025-10-29 | 0.94 | 11.37B |
| 2025-07-30 | 1.02 | 11.14B |
| 2025-04-30 | 0.76 | 10.36B |
| 2024-10-31 | 0.94 | 10.63B |
| 2025-10-29 | 0.94 | 10.63B |

### Revenue and Profitability
-----------------------------

| Quarter | Revenue | Profit Margin |
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

### Capital and Profitability
---------------------------

| Quarter | Equity | ROE |
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

### Comprehensive Analysis
-------------------------

Based on the provided analysis, Abbott Laboratories (ABT) has a diverse set of characteristics. The return rate of 36.06% is lower compared to the S&P 500 (VOO) return rate of 92.89%, indicating a certain level of divergence. The Alpha, Beta analysis reveals a mix of positive and negative returns across different time periods. The recent stock price fluctuations indicate a positive trend, with the 5-day, 20-day, and 60-day SMA all above the close price. However, the MRI (Market Risk Indicator) is at a moderate level of 0.70, indicating a medium-risk investment.

The RSI, PPO analysis indicates a Buy signal, with an Expected Return of -1586.60%. Recent news and events suggest a mixed picture, with both positive and negative developments.

The analyst opinions are generally bullish, with a consensus rating of Buy and a mean rating of 1.71 (~Buy). The target price is estimated to be around $144.75, with an average/ high/low range of $169.00 / $144.75 / $122.00.

The recent earnings analysis indicates a stable revenue growth, with a mix of positive and negative EPS. The revenue and profitability analysis reveals a stable profit margin across different time periods. The capital and profitability analysis indicates a moderate level of equity and ROE.

In conclusion, the comprehensive analysis suggests that Abbott Laboratories (ABT) has a mixed set of characteristics, with both positive and negative trends. Investors should carefully weigh the risks and opportunities before making investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.